GLP-1 spillover, AI empowerment... Will biopharmaceuticals be the "alternative" to tech stocks in 2026?
Due to attractive valuations, the recovery of business development (BD) and IPO activities, and a series of key catalysts, the biopharmaceutical sector is showing strong growth potential in 2026. Although the industry’s overall revenue and earnings growth expectations are slightly below market average, its low-risk profile and strong pipeline